Imunon Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. PROPERTIES
| ITEM 2. | PROPERTIES |
|---|
We own no real property and have no plans to acquire any real property in the future.
Lawrenceville, NJ Lease
In August 2023, the Company renewed its Lawrenceville office lease for a 24-month agreement for 9,850 square feet with monthly rent payments of approximately $22,983 and $23,394.
Huntsville, AL Lease
In January 2023, the Company renewed its Huntsville facility lease for a 60-month lease agreement for 11,420 square feet with monthly rent payments of approximately $28,550 to $30,903.
We believe our existing facilities are suitable and adequate to conduct our business.
Following is a table of future payments and maturity of our operating lease liabilities as of December 31, 2023:
| For the year ending December 31, | |
|---|---|
| 2024 | $626,323 |
| 2025 | 543,009 |
| 2026 | 362,976 |
| 2027 | 370,236 |
| 2028 and thereafter | 30,903 |
| Subtotal future lease payments | 1,933,447 |
| Less imputed interest | (308,733) |
| Total lease liabilities | $1,624,714 |
| Weighted average remaining life | 3.5 years |
| Weighted average discount rate | 9.98% |
For 2023, operating lease expense was $646,633 and cash paid for operating leases included in operating cash flows was $644,593. For 2022, operating lease expense was $587,744 and cash paid for operating leases included in operating cash flows was $601,495.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.